| The proto-oncogene c-myc acts through the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1) to facilitate the activation of Cdk4/6 and early G(1) phase progression. | None |
| Effects of fluid shear stress on expression of proto-oncogenes c-fos and c-myc in cultured human umbilical vein endothelial cells. | None |
| Effects of fluid shear stress on expression of proto-oncogenes c-fos and c-myc in cultured human umbilical vein endothelial cells. | None |
| The expression of the developmentally regulated proto-oncogene Pax-3 is modulated by N-Myc. | None |
| Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations. | None |
| the in vitro effects of iron on the proliferation of a primary, human synovial fibroblast cell line and the involvement of c-myc in this process as a model for c-myc proto-oncogene expression in hemophilic synovitis | None |
| c-myc proto-oncogene expression in hemophilic synovitis: in vitro studies of the effects of iron and ceramide. | None |
| Transcription from the tartrate-resistant acid phosphatase promoter is negatively regulated by the Myc oncoprotein. | None |
| Quantitative proteomic analysis of Myc oncoprotein function. | None |
| Role of Oncogenic Transcription Factor c-Myc in Cell Cycle Regulation, Apoptosis and Metabolism. | None |
| Upregulation of the oncogene c-myc in Barrett s adenocarcinoma: induction of c-myc by acidified bile acid in vitro. | None |
| The c-Myc Oncoprotein Interacts with Bcr. | None |
| Functional analysis of the N-terminal domain of the Myc oncoprotein. | None |
| Repression of the TMEFF2 promoter by c-Myc. | None |
| Random mutagenesis of PDZ(Omi) domain and selection of mutants that specifically bind the Myc proto-oncogene and induce apoptosis. | None |
| Identification of a novel Kruppel-associated box domain protein, Krim-1, that interacts with c-Myc and inhibits its oncogenic activity. | None |
| The MYC oncogene as a cancer drug target. | None |
| Mutual interference of adenovirus infection and myc expression. | None |
| expression of MYC oncogene is reduced at the mRNA level and MYC protein has an increased half-life in Adenovirus infected Hela cells resulting in constant steady state levels. | None |
| c-Myc oncoprotein: cell cycle-related events and new therapeutic challenges in cancer and cardiovascular diseases. | None |